Add to ORKGThe immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines: a 2 randomised clinical trial in UK adults.
Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason,...
Meningococcal disease, presenting primarily as meningococcemia and meningitis, continues to be a dev...
AbstractBackgroundQuadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer lo...
Meningococcal conjugate vaccines are today successfully deployed in universal programs for children ...
adults. A and C polysaccharide conjugate vaccine in Safety and immunogenicity of meningococca
Meningococcal polysaccharide (Men-Ps) vaccine immunogenicity following either primary immunization o...
Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disea...
It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal p...
Thirty-four adults were vaccinated with 1/50 of the usual dose of meningococcal polysaccharide vacci...
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used succe...
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used succe...
Background. Group A Neisseria meningitidis has been a major cause of bacterial meningitis in the sub...
Meningococcal meningitis represents one of the leading cause of bacterial meningitis in developed co...
Objective. - To assess the safety and immunogenicity of a bivalent serogroups A/C meningococcal olig...
Background/PurposeMeningococcal disease, including meningitis and sepsis, usually follows an invasiv...
Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason,...
Meningococcal disease, presenting primarily as meningococcemia and meningitis, continues to be a dev...
AbstractBackgroundQuadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer lo...
Meningococcal conjugate vaccines are today successfully deployed in universal programs for children ...
adults. A and C polysaccharide conjugate vaccine in Safety and immunogenicity of meningococca
Meningococcal polysaccharide (Men-Ps) vaccine immunogenicity following either primary immunization o...
Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disea...
It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal p...
Thirty-four adults were vaccinated with 1/50 of the usual dose of meningococcal polysaccharide vacci...
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used succe...
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used succe...
Background. Group A Neisseria meningitidis has been a major cause of bacterial meningitis in the sub...
Meningococcal meningitis represents one of the leading cause of bacterial meningitis in developed co...
Objective. - To assess the safety and immunogenicity of a bivalent serogroups A/C meningococcal olig...
Background/PurposeMeningococcal disease, including meningitis and sepsis, usually follows an invasiv...
Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason,...
Meningococcal disease, presenting primarily as meningococcemia and meningitis, continues to be a dev...
AbstractBackgroundQuadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer lo...